儿童遗传性骨髓衰竭
遗传性骨髓衰竭综合征是一组以骨髓衰竭为特征、通常伴至少一种造血外异常的疾病,常在儿童期发病,部分初诊为特发性再生障碍性贫血或骨髓增生异常者实为隐匿病例。遗传学进展已鉴定逾100个疾病基因,揭示DNA修复、端粒维持和核糖体生物发生等通路;基于氟达拉滨的造血干细胞移植显著改善了范可尼贫血或先天性角化不良患者的结局。
要点
- 遗传性骨髓衰竭综合征常伴造血外异常,部分初诊为特发性再生障碍性贫血或骨髓增生异常者实为隐匿病例。
- 已鉴定逾100个疾病基因,涉及DNA修复、端粒维持和核糖体生物发生等通路。
- 基于氟达拉滨的造血干细胞移植显著改善了范可尼贫血或先天性角化不良患者的结局。
核心结论
- 遗传学进展促进了遗传性骨髓衰竭综合征的诊断,基于氟达拉滨的造血干细胞移植显著改善了范可尼贫血或先天性角化不良患者的结局,但癌症等部分并发症的管理仍是挑战,靶向疾病特异性缺陷的新疗法(如转化生长因子-β抑制剂用于范可尼贫血、PAPD5抑制剂用于先天性角化不良)尚在探索中。
研究设计与样本
- 综述,总结遗传性骨髓衰竭综合征的遗传学、临床诊断与治疗进展。
主要发现
- 遗传性骨髓衰竭综合征可累及至少一个细胞谱系,常在儿童期发病,部分初诊为特发性再生障碍性贫血或骨髓增生异常者实为隐匿病例。
- 已鉴定逾100个疾病基因,涉及DNA修复(范可尼贫血基因)、端粒维持(先天性角化不良基因)和核糖体生物发生(Shwachman-Diamond综合征和Diamond-Blackfan贫血基因)等通路。
- 基于氟达拉滨的造血干细胞移植显著改善了范可尼贫血或先天性角化不良患者的结局。
- 近期研究提示转化生长因子-β抑制剂用于范可尼贫血、PAPD5抑制剂用于先天性角化不良等靶向疾病特异性缺陷的新疗法可能有效。
临床怎么用
- 遗传学进展带来的基因检测有助于诊断,尤其当临床特征不足以准确分类疾病时。
- 基于氟达拉滨的造血干细胞移植用于改善范可尼贫血或先天性角化不良患者的结局。
- 癌症等部分并发症的管理仍是挑战。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Inherited bone marrow (BM) failure syndromes are a diverse group of disorders characterized by BM failure, usually in association with ≥1 extrahematopoietic abnormalities. BM failure, which can involve ≥1 cell lineages, often presents in the pediatric age group. Furthermore, some children initially labeled as having idiopathic aplastic anemia or myelodysplasia represent cryptic cases of inherited BM failure. Significant advances in the genetics of these syndromes have been made, identifying more than 100 disease genes, giving insights into normal hematopoiesis and how it is disrupted in patients with BM failure. They have also provided important information on fundamental biological pathways, including DNA repair: Fanconi anemia (FA) genes; telomere maintenance: dyskeratosis congenita (DC) genes; and ribosome biogenesis: Shwachman-Diamond syndrome and Diamond-Blackfan anemia genes. In addition, because these disorders are usually associated with extrahematopoietic abnormalities and increased risk of cancer, they have provided insights into human development and cancer. In the clinic, genetic tests stemming from the recent advances facilitate diagnosis, especially when clinical features are insufficient to accurately classify a disorder. Hematopoietic stem cell transplantation using fludarabine-based protocols has significantly improved outcomes, particularly in patients with FA or DC. Management of some other complications, such as cancer, remains a challenge. Recent studies have suggested the possibility of new and potentially more efficacious therapies, including a renewed focus on hematopoietic gene therapy and drugs [transforming growth factor-β inhibitors for FA and PAPD5, a human poly(A) polymerase, inhibitors for DC] that target disease-specific defects.
引用
- Dokal I, Tummala H, Vulliamy T, et al. Inherited bone marrow failure in the pediatric patient. Blood. 2022. PMID: 35605178. doi:10.1182/blood.2020006481
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。